![](/images/graphics-bg.png)
The Role of Combination Maintenance with Pemetrexed and Bevacizumab for Advanced Stage Nonsquamous Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
المؤلفون المشاركون
Min-he, Shen
Shan, Feiyu
Zhang, Bo
Sun, Leitao
Xie, Lufan
Ruan, Shanming
المصدر
العدد
المجلد 2018، العدد 2018 (31 ديسمبر/كانون الأول 2018)، ص ص. 1-14، 14ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2018-05-28
دولة النشر
مصر
عدد الصفحات
14
التخصصات الرئيسية
الملخص EN
Purpose.
To evaluate the effect of combination maintenance therapy of pemetrexed plus bevacizumab for patients with advanced non-small cell lung cancer.
Methods.
We identified relevant studies by electronic search (Embase, PubMed, Cochrane, and Web of Science from 1 January 1960 to 29 October 2016) and manual search.
The primary outcome of interest was progression-free survival (PFS) and secondary end point included overall survival (OS) and toxicities.
The data was pooled for quantitative analysis and the final effect size was reported as hazard ratio (HR) for survival outcomes and relative risk (RR) for safety outcomes, both with a random-effects model.
Results.
Three randomized controlled trials enrolling 1302 patients with advanced non-small cell lung cancer were included in this meta-analysis.
An evident PFS improvement (HR = 0.73, 95% CI = 0.63–0.83, P < 0.01) was observed in patients with pemetrexed and bevacizumab combination maintenance therapy compared with single-agent maintenance therapy, yet it did not subsequently lead to a significant improvement in OS (HR = 0.97, 95% CI = 0.84–1.10, P = 0.66).
Our analysis also showed statistically increased risks for provoking grade 3-4 adverse events in patients managed using pemetrexed plus bevacizumab combination (RR = 1.59, 95% CI = 1.07–2.36, P = 0.022).
Conclusions.
Pemetrexed plus bevacizumab combination maintenance therapy leads to significant improvement in PFS but not in OS for patients with advanced non-small cell lung cancer, which also increases the risks of grade 3-4 adverse events.
Yet, in view of the limitation of existing studies and this meta-analysis, current evidence is not adequate to support routine use of pemetrexed-bevacizumab maintenance.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Shan, Feiyu& Zhang, Bo& Sun, Leitao& Xie, Lufan& Min-he, Shen& Ruan, Shanming. 2018. The Role of Combination Maintenance with Pemetrexed and Bevacizumab for Advanced Stage Nonsquamous Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. BioMed Research International،Vol. 2018, no. 2018, pp.1-14.
https://search.emarefa.net/detail/BIM-1127573
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Shan, Feiyu…[et al.]. The Role of Combination Maintenance with Pemetrexed and Bevacizumab for Advanced Stage Nonsquamous Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. BioMed Research International No. 2018 (2018), pp.1-14.
https://search.emarefa.net/detail/BIM-1127573
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Shan, Feiyu& Zhang, Bo& Sun, Leitao& Xie, Lufan& Min-he, Shen& Ruan, Shanming. The Role of Combination Maintenance with Pemetrexed and Bevacizumab for Advanced Stage Nonsquamous Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. BioMed Research International. 2018. Vol. 2018, no. 2018, pp.1-14.
https://search.emarefa.net/detail/BIM-1127573
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1127573
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
![](/images/ebook-kashef.png)
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر
![](/images/kashef-image.png)